Three more years as an LDC: what Bangladesh should buy with the time

On 29 October 2026 the UN General Assembly gave Bangladesh three more years. The country was due to leave the UN's group of least developed countries on 24 November 2026. The date is now 24 November 2029¹. Three years is a long time in trade policy and a short time in medicine. The question is not whether Bangladesh deserved the delay. It is what the country buys with it.

What changed?

In February the new government asked the UN for a three-year extension of the preparatory period, citing global shocks, economic strain and political upheaval. The UN's Committee for Development Policy agreed that an extension was appropriate, but advised a shorter one². In July the UN Economic and Social Council passed the request to the General Assembly without recommending a length³. On 29 October the Assembly granted the full three years, on a draft tabled by Uruguay for the G-77, with no country objecting⁴. The resolution calls it an exceptional decision.

The committee attached a condition that matters more than the date. The extra time is for reform: financial sector stability, tax revenue, diversification and preparing private firms. It also said it does not foresee supporting any further extension⁵. This is the last one. And trade preferences in the extra years still depend on each importing country's own rules¹.

What three years of LDC status are worth

The obvious value is trade. Bangladesh uses about 67% of the trade benefits offered to all 44 LDCs, and about 73% of its exports are linked to LDC preferences, by the estimates of Mohammad Abdur Razzaque, chairman of the research group RAPID⁶. UNCTAD has estimated that exports could fall by more than $17.5 billion⁷, about a third, if those preferences were lost. Apparel carries most of that weight.

The less obvious value is medicine, and for health it is the bigger one.

The medicine clock

In 2025 local companies supplied about 98%⁸ of the medicines Bangladesh uses, in a market worth more than $3.5 billion, and exported to more than 160 countries. Much of that rests on one rule. As an LDC, Bangladesh does not have to apply full patent protection to medicines under the WTO's TRIPS agreement, so local firms can make drugs that are still patented elsewhere.

About 20% of the drugs made in Bangladesh are still under patent, by the estimate of Mustafizur Rahman, a distinguished fellow at the Centre for Policy Dialogue. Citing a South Centre study, he has said insulin prices could rise eightfold⁸ without the exemption. The industry also imports about $1.2 billion of active ingredients a year, and of the 42 plots set aside for ingredient makers in the park announced in 2008, only four were working in 2025⁸.

The warning sign in 2025 was not a price. It was a queue: more than 1,000⁹ applications for generic and biosimilar medicines, including cancer drugs, had waited about two and a half years for a decision, while the industry argued that registering them before graduation was the way to keep them cheap afterwards. The extra time is worth most if that queue gets cleared, not if it gets three more years to grow.

Reform, not rest

The committee's conditions point at the real weaknesses. Tax revenue was about 6.8%¹⁰ of GDP in 2025-26 on provisional figures, one of the lowest ratios in the world. Classified loans were 32.78%¹¹ of bank lending at the end of June 2026. External debt service was about $4.5 billion in 2025-26¹² and is projected at about $7.6 billion by 2028-29¹³. None of those get easier by waiting, and graduation in 2029 will arrive with or without the work done.

What I would do with the three years

I have seen the parts of this up close, from the patient's side of a Bangladeshi health business. At Praava Health most patients paid out of pocket, so every price was visible and compared. When we replaced referral kickbacks with transparent pricing, lab margins moved from about 30% to 50% while prices for patients came down. Efficiency can absorb cost, if you design for it.

At SureCash we delivered a government stipend to about 10 million beneficiaries on mobile money. That is the tool for the hardest case: if some patented medicines do get more expensive after 2029, a targeted subsidy for people on insulin or cancer treatment, paid on digital rails, costs far less than keeping every price low for everyone.

So the list I would put in front of a health ministry, a drug maker or a hospital group is short:

• Clear the registration queue now. Every generic registered before graduation is a price that stays low after it.
• Build the ingredient base. Gas and power for the ingredient park are an industrial policy problem with a health outcome.
• Know which medicines are exposed. List the patented drugs patients depend on, the patent end dates, and the licences worth negotiating early.
• Design the targeted subsidy before it is needed. The payment rails already exist. The eligibility rules and the budget do not.
• Treat the revenue gap as a health issue. A state that collects less than 7% of GDP in tax cannot pay for medicines, primary care or the subsidy above.

For US readers the lesson runs the other way. The US already lives under full patent rules and knows what a medicine with no generic competitor costs. Bangladesh joins that world in 2029. A Bangladesh that graduates ready keeps making affordable medicines for its own patients and for export; one that graduates unready imports more of them at higher prices.

The short version

• Graduation moved from 24 November 2026 to 24 November 2029, granted by the UN General Assembly on 29 October 2026 as an exceptional decision.
• The condition is reform: tax revenue, banks and private-sector readiness. The UN's development committee does not foresee supporting another extension.
• Trade benefits can run three more years, subject to each importing country's rules; about 73% of exports are linked to LDC preferences.
• Medicines are the health risk: about 98% are made locally, about 20% of local drugs are still patented, and insulin prices could rise eightfold without the exemption, by one study.
• Use the time: clear the drug registration queue, build the ingredient base, map the exposed medicines and design a targeted subsidy.

If your organisation buys, makes or prescribes medicines in Bangladesh, which three drugs would you protect first, and is anyone already working on them?

Md Shafaat Ali Choyon (MPH, CHES®, MBA, MCIM) is a growth, marketing and public-health strategist who builds and runs AI in production, with 17 years across telecom, fintech, e-commerce, consumer tech and healthcare in the US and Bangladesh. See the essays or the portfolio.